CHICAGO (CBS) -- The Red Cross mission to prevent and relieve human suffering continues even when there's not an emergency, ...
Transplant is beneficial earlier in life, Wang told MedPage Today, but carries potential short- and long-term side effects.
Called Casgevy, the gene-editing treatment is for people with sickle cell disease and a related blood disorder called beta thalassemia. UK regulators approved the treatment in November 2023 ...
SAN DIEGO — The approval one year ago of two genetic medicines for sickle cell disease, including the first therapy powered by CRISPR gene editing, was a milestone for people living with a ...
SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in ...
University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...
BMS isn’t the only firm trying to use degraders to tackle sickle cell disease. Novartis has a Wiz-targeting glue degrader, ...
A new trial called BEACON, led at Boston Childrens Hospital by Dr. Matthew Heeney and sponsored by Beam Therapeutics, is testing base editing as a way to boost fetal hemoglobin production in patients ...
Sickle cell disease is a condition little understood by most people around the world, despite it being the number one most ...
As he got older, he learned he had sickle cell disease. His red blood cells were forming sickle shapes and getting stuck in his blood stream, preventing oxygen from reaching his tissues.